STOCK TITAN

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

2seventy bio, Inc. (Nasdaq: TSVT) will report its first quarter 2024 financial results on May 8, 2024. The company aims to accelerate cancer treatment development by leveraging cell therapies. They focus on delivering the first FDA-approved CAR T cell therapy for multiple myeloma. 2seventy bio emphasizes speed and efficacy in translating human thought into action, aiming to give patients more time. The company maintains a genuine approach and prioritizes its people and culture.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET.

Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event’s start. A replay of the call will be available on the 2seventy bio website following the completion of the call.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

Investors:

Vicki Eatwell, CFO

vicki.eatwell@2seventybio.com



Jenn Snyder

Jenn.snyder@2seventybio.com



Media:

Jenn Snyder

Jenn.snyder@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

When will 2seventy bio report its first quarter 2024 financial results?

2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.

What is the focus of 2seventy bio in cancer treatment development?

2seventy bio focuses on delivering the first FDA-approved CAR T cell therapy for multiple myeloma.

What is the mission of 2seventy bio?

2seventy bio aims to work at the maximum speed of translating human thought into action to give patients more time.

Where can participants access the conference call for 2seventy bio's financial results?

Participants can access the conference call live via webcast available on the Investors and Media page of the company’s website at https://ir.2seventybio.com.

How can participants ask questions during the conference call?

Participants who wish to ask a question may register to receive dial-in numbers and a unique pin to join the call.

2seventy bio, Inc.

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Stock Data

233.89M
49.61M
2.5%
98.41%
13.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About TSVT

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer